Press Release: Viriom : Viriom Announces Initiation of Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV-Infected Patients
SAN DIEGO, May 4, 2020 /PRNewswire/ --Â Viriom Inc (Viriom) announced today the initiation of a Phase 2a study investigating the efficacy of an intramuscular long-acting injectable nanoformulation of VM1500A in HIV-infected patients....
Read full article »
Viriom is a biotech company that develops and commercializes novel therapies for the treatment of life threatening infections such as HIV and HBV.
Read more